Dicot Pharma
0,219
SEK
-0,68 %
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 investor følger denne virksomhed
-0,68%
+4,3%
+1,16%
+9,42%
-6,58%
+71,73%
-35,67%
-76,75%
-91,45%
www.dicotpharma.com/investor-relations
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.
Omsætning
230 t
EBIT %
-19.569,57 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
DICOT
Daglig lav / høj pris
0,214 / 0,22
SEK
Markedsværdi
388,66 mio. SEK
Aktieomsætning
314,22 t SEK
Volumen
1,5 mio.
Finanskalender
Årsrapport
13.02.2025
Delårsrapport
29.04.2025
Generalforsamling
06.05.2025
Delårsrapport
12.08.2025
Delårsrapport
23.10.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Avanza Pension | 10,5 % | 10,5 % |
| Bertil Lindkvist (Ålandsbanken) | 7,6 % | 7,6 % |
| Nordnet Pensionsförsäkring | 3,6 % | 3,6 % |
| Tor Finans AB | 3,2 % | 3,2 % |
| Torsten Söderberg med familj | 1,9 % | 1,9 % |
| Stefan Henriksson | 1,3 % | 1,3 % |
| Christian och Gerd Lentz | 1,2 % | 1,2 % |
| Klas Göran Strömberg | 1,0 % | 1,0 % |
| Michael Zell | 0,9 % | 0,9 % |
| Wilhelm Risberg | 0,9 % | 0,9 % |
ViserAlle indholdstyper
Dicot Pharma AB: First participants dosed in Dicot Pharma's Phase 2a clinical study
Dicot Pharma AB: International business development expert joins Dicot Pharma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools